Frontier Capital Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,836,873
| Closed | -$52.6M | – | 295 |
|
|
2024
Q2 | $52.6M | Sell |
1,836,873
-77,470
| -4% | -$2.2M | 0.52% | 67 |
|
|
2024
Q1 | $55.9M | Sell |
1,914,343
-170,199
| -8% | -$5.23M | 0.52% | 61 |
|
|
2023
Q4 | $70.3M | Buy |
2,084,542
+285,045
| +16% | +$8.34M | 0.71% | 36 |
|
|
2023
Q3 | $55.2M | Buy |
1,799,497
+114,242
| +7% | +$4.12M | 0.61% | 52 |
|
|
2023
Q2 | $67.5M | Buy |
1,685,255
+81,171
| +5% | +$3.36M | 0.65% | 49 |
|
|
2023
Q1 | $65.5M | Buy |
1,604,084
+542,661
| +51% | +$21.6M | 0.68% | 52 |
|
|
2022
Q4 | $41M | Sell |
1,061,423
-73,564
| -6% | -$3.58M | 0.45% | 87 |
|
|
2022
Q3 | $60.4M | Buy |
1,134,987
+72,320
| +7% | +$4.02M | 0.71% | 38 |
|
|
2022
Q2 | $62M | Buy |
1,062,667
+7,945
| +0.8% | +$520K | 0.71% | 31 |
|
|
2022
Q1 | $80.5M | Buy |
1,054,722
+124,851
| +13% | +$8.32M | 0.73% | 37 |
|
|
2021
Q4 | $56M | Buy |
929,871
+135,927
| +17% | +$7.49M | 0.44% | 76 |
|
|
2021
Q3 | $44.5M | Sell |
793,944
-18,129
| -2% | -$1.04M | 0.35% | 106 |
|
|
2021
Q2 | $49.3M | Sell |
812,073
-226,302
| -22% | -$14.3M | 0.36% | 106 |
|
|
2021
Q1 | $72.8M | Buy |
1,038,375
+6,178
| +0.6% | +$441K | 0.55% | 57 |
|
|
2020
Q4 | $61.8M | Sell |
1,032,197
-51,901
| -5% | -$3.04M | 0.46% | 75 |
|
|
2020
Q3 | $65.2M | Sell |
1,084,098
-20,593
| -2% | -$1.2M | 0.57% | 58 |
|
|
2020
Q2 | $58M | Buy |
1,104,691
+25,019
| +2% | +$1.05M | 0.51% | 65 |
|
|
2020
Q1 | $36.2M | Sell |
1,079,672
-269,977
| -20% | -$11.2M | 0.41% | 90 |
|
|
2019
Q4 | $61.1M | Sell |
1,349,649
-328,835
| -20% | -$14M | 0.45% | 82 |
|
|
2019
Q3 | $63.9M | Buy |
1,678,484
+63,613
| +4% | +$2.54M | 0.5% | 65 |
|
|
2019
Q2 | $70.2M | Buy |
1,614,871
+235,246
| +17% | +$9.99M | 0.53% | 62 |
|
|
2019
Q1 | $52.5M | Buy |
+1,379,625
| New | +$53.8M | 0.37% | 110 |
|
|
2017
Q3 | – | Sell |
-123,857
| Closed | -$5.91M | – | 325 |
|
|
2017
Q2 | $5.91M | Sell |
123,857
-3,058
| -2% | -$142K | 0.04% | 267 |
|
|
2017
Q1 | $5.79M | Buy |
126,915
+48,179
| +61% | +$2.08M | 0.04% | 265 |
|
|
2016
Q4 | $2.54M | Sell |
78,736
-5,012
| -6% | -$167K | 0.02% | 275 |
|
|
2016
Q3 | $2.87M | Sell |
83,748
-18,496
| -18% | -$725K | 0.02% | 280 |
|
|
2016
Q2 | $3.45M | Sell |
102,244
-63,218
| -38% | -$3.11M | 0.03% | 277 |
|
|
2016
Q1 | $8.77M | Sell |
165,462
-24,284
| -13% | -$1.42M | 0.07% | 245 |
|
|
2015
Q4 | $14.6M | Buy |
+189,746
| New | +$10.7M | 0.12% | 215 |
|
Other funds holding PCRX
DPCM
Frontier Capital Management's PCRX Position: Q3 2024 in Review
Frontier Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 1,836,873 shares — an estimated $52.6M sold.
Frontier Capital Management first reported a position in PCRX in Q4 2015 and held it in 29 quarters. The position peaked at $80.5M in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.
- Frontier Capital Management reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
- Frontier Capital Management sold 1,836,873 Pacira BioSciences shares in Q3 2024, an estimated $52.6M.
- Frontier Capital Management first reported a position in Pacira BioSciences in Q4 2015 and held it in 29 quarters.
- Frontier Capital Management's Pacira BioSciences position peaked at $80.5M in Q1 2022.
- 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.
Based on Frontier Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.